RU2589053C1 - ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ - Google Patents

ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ Download PDF

Info

Publication number
RU2589053C1
RU2589053C1 RU2014147863/04A RU2014147863A RU2589053C1 RU 2589053 C1 RU2589053 C1 RU 2589053C1 RU 2014147863/04 A RU2014147863/04 A RU 2014147863/04A RU 2014147863 A RU2014147863 A RU 2014147863A RU 2589053 C1 RU2589053 C1 RU 2589053C1
Authority
RU
Russia
Prior art keywords
compound
pyrrolo
methyl
mmol
reaction
Prior art date
Application number
RU2014147863/04A
Other languages
English (en)
Russian (ru)
Inventor
Чуньхао ЯН
Линхуа МЭН
Яньхун ЧЭНЬ
Сян Ван
Цунь ТАНЬ
Цзяпэн ЛИ
Цзянь ДИН
И Чэнь
Original Assignee
Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз
Шанхай Грин Вэлли Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз, Шанхай Грин Вэлли Фармасьютикал Ко., Лтд. filed Critical Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз
Application granted granted Critical
Publication of RU2589053C1 publication Critical patent/RU2589053C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
RU2014147863/04A 2012-05-31 2013-04-23 ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ RU2589053C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210177980.3A CN103450204B (zh) 2012-05-31 2012-05-31 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CN201210177980.3 2012-05-31
PCT/CN2013/074559 WO2013177983A1 (zh) 2012-05-31 2013-04-23 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Publications (1)

Publication Number Publication Date
RU2589053C1 true RU2589053C1 (ru) 2016-07-10

Family

ID=49672377

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014147863/04A RU2589053C1 (ru) 2012-05-31 2013-04-23 ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Country Status (14)

Country Link
US (1) US9447101B2 (zh)
EP (1) EP2857403B1 (zh)
JP (1) JP6067107B2 (zh)
KR (1) KR101824299B1 (zh)
CN (1) CN103450204B (zh)
AU (1) AU2013270326B2 (zh)
BR (1) BR112014029708B1 (zh)
CA (1) CA2874062C (zh)
ES (1) ES2703934T3 (zh)
HK (1) HK1203499A1 (zh)
MX (1) MX359207B (zh)
RU (1) RU2589053C1 (zh)
SG (1) SG11201407752YA (zh)
WO (1) WO2013177983A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771311C2 (ru) * 2017-08-15 2022-04-29 Сиэсписи Чжунци Фармасьютикал Текнолоджи (Шишцзяжуан) Ко., Лтд. Ингибитор fgfr и его медицинское применение

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
EP2948454B1 (en) 2013-01-24 2017-05-31 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Triazine compounds and a process for preparation thereof
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017040448A1 (en) * 2015-08-31 2017-03-09 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CA3028822C (en) * 2016-06-25 2021-06-22 Suzhou Kintor Pharmaceuticals, Inc. Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2022003217A (es) 2019-09-19 2022-06-29 Totus Medicines Inc Conjugados terapeuticos.
CN112851563A (zh) * 2020-12-30 2021-05-28 安徽金鼎医药股份有限公司 N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺
WO2023035614A1 (zh) * 2021-09-10 2023-03-16 上海海和药物研究开发股份有限公司 包含PI3Kα抑制剂的药物组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2011089400A1 (en) * 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
WO2011141713A1 (en) * 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
RU2448109C2 (ru) * 2006-08-08 2012-04-20 Чугаи Сейяку Кабусики Кайся Производное пиримидина в качестве ингибитора pi3k и его применение

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
KR101460816B1 (ko) * 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
US8148522B2 (en) 2007-01-02 2012-04-03 Bristol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
EP2212333A1 (en) * 2007-10-16 2010-08-04 Wyeth LLC Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010092340A1 (en) * 2009-02-13 2010-08-19 Ucb Pharma S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
EP2419429B1 (en) * 2009-04-16 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines as inhibitors of protein kinases
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448109C2 (ru) * 2006-08-08 2012-04-20 Чугаи Сейяку Кабусики Кайся Производное пиримидина в качестве ингибитора pi3k и его применение
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2011089400A1 (en) * 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
WO2011141713A1 (en) * 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771311C2 (ru) * 2017-08-15 2022-04-29 Сиэсписи Чжунци Фармасьютикал Текнолоджи (Шишцзяжуан) Ко., Лтд. Ингибитор fgfr и его медицинское применение

Also Published As

Publication number Publication date
BR112014029708A8 (pt) 2021-09-08
HK1203499A1 (zh) 2015-10-30
ES2703934T3 (es) 2019-03-13
WO2013177983A1 (zh) 2013-12-05
CN103450204B (zh) 2016-08-17
BR112014029708B1 (pt) 2023-05-02
EP2857403A1 (en) 2015-04-08
AU2013270326B2 (en) 2016-07-14
CA2874062A1 (en) 2013-12-05
US9447101B2 (en) 2016-09-20
KR20150009565A (ko) 2015-01-26
SG11201407752YA (en) 2015-01-29
JP6067107B2 (ja) 2017-01-25
JP2015518010A (ja) 2015-06-25
EP2857403A4 (en) 2015-10-21
KR101824299B1 (ko) 2018-03-14
US20150141644A1 (en) 2015-05-21
MX2014014622A (es) 2015-08-10
CA2874062C (en) 2015-09-22
EP2857403B1 (en) 2018-10-10
CN103450204A (zh) 2013-12-18
BR112014029708A2 (pt) 2017-06-27
AU2013270326A1 (en) 2014-12-18
MX359207B (es) 2018-09-19

Similar Documents

Publication Publication Date Title
RU2589053C1 (ru) ПИРРОЛО[2,1-f][1,2,4]ТРИАЗИНОВОЕ СОЕДИНЕНИЕ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP5766820B2 (ja) Ｐｉ３キナーゼ阻害剤としての複素環化合物
WO2022061251A1 (en) Compounds and methods for kras modulation and indications therefor
ES2718218T3 (es) Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína cinasa 1 D/E
JP5677425B2 (ja) Ｐｉ３ｋ阻害剤としてのピリミジノン
ES2395835T3 (es) Inhibidores de la proteína quinasa bicíclicos
JP4134227B2 (ja) 縮合複素環化合物
IL274938B1 (en) New compounds and their pharmaceutical preparations for the treatment of diseases
JP5581390B2 (ja) Ａｋｔ阻害剤
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
AU2010300719A1 (en) PI3K (delta) selective inhibitors
CA2669686A1 (en) 7-substituted purine derivatives for immunosuppression
JP7383112B2 (ja) アルキン誘導体およびその調製方法と用途
JP2021176901A (ja) 縮合複素環化合物
WO2020077944A1 (zh) 嘌呤系列衍生物及其制备方法和用途
JP2013530250A (ja) 二環式ピリミジン化合物
JP5886868B2 (ja) 置換ピリミド［１，２−ｂ］インダゾールおよびＰＩ３Ｋ／ＡＫＴ経路のモジュレーターとしてのそれらの使用
WO2024083773A1 (en) Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20170831